Elsevier

Gastrointestinal Endoscopy

Volume 50, Issue 5, November 1999, Pages 618-622
Gastrointestinal Endoscopy

Relationship of low-dose aspirin to Gl injury and occult bleeding: A pilot study

https://doi.org/10.1016/S0016-5107(99)80008-XGet rights and content

Background: Low-dose aspirin is commonly used in patients with cardiovascular disease. However, little is known about the effect of aspirin on occult blood loss caused by gastrointestinal injury. Therefore, we studied endoscopic injury and fecal occult blood loss in patients ingesting different quantities of low-dose aspirin.

Methods: Forty healthy volunteers were enrolled in a randomized, double-blind, prospective, pilot endoscopic study. Each volunteer underwent 30 days of treatment with dally aspirin 30 mg, 81 mg, 325 mg, or placebo. Subjects completed fecal occult blood test cards before and at the end of treatment of two types: guaiac impregnated (Hemoccult and Hemoccult SENSA) and immunochemical (Hemeselect and FlexSure OBT). Each volunteer underwent upper endoscopy at baseline and after completing 30 days of study medication.

Results: Aspirin did not induce significant injury as determined by endoscopy when compared with placebo. Six of 30 volunteers taking aspirin developed erosions, whereas 1 of 10 subjects on placebo developed a new erosion (p=0.66). Aspirin 325 mg was associated with a higher mean symptom score than the lower aspirin dosages and the placebo group (p=0.12). Only one subject taking aspirin (325 mg) had fecal occult blood on a single HemeSelect card. No subject had a positive fecal occult blood test with Hemoccult II, Hemoccult II SENSA, or FlexSure OBT cards.

Conclusions: Aspirin in dosages commonly used for cardiovascular prophylaxis does not generally cause significant gastric or duodenal mucosal endoscopic lesions. In the absence of frank ulceration, low-dose aspirin does not result in positive fecal occult blood tests. Low-dose aspirin should not interfere with fecal occult blood testing and probably should not be stopped during stool collection.

References (13)

There are more references available in the full text version of this article.

Cited by (22)

  • Tests and investigations for colorectal cancer screening

    2014, Clinical Biochemistry
    Citation Excerpt :

    A meta-analysis [92] and more recently a systematic review [93] support decisions made in the England (and elsewhere) not to impose dietary restrictions as part of the gFOBt screening process. The test positivity of gFOBt may also be affected in individuals with an increased likelihood of bleeding (e.g. those taking drugs such as warfarin or aspirin) [94,95], although some evidence suggests otherwise [96–98]. Current advice is that withdrawal of NSAIDs and anticoagulant drugs before participating in CRC screening using gFOBt is not necessary [98].

  • Gastrointestinal malignancies and cardiovascular diseases-Non-negligible comorbidity in an era of multi-antithrombotic drug use

    2011, Journal of Cardiology
    Citation Excerpt :

    Several clinical studies, although not large-scale, have been designed to answer this question. In a double-blind, prospective study, Greenberg et al. reported that, in the absence of frank ulceration, low-dose aspirin did not result in a positive FOBT [29]. In that study, however, healthy volunteers underwent only 30 days of treatment with daily aspirin or placebo.

  • Performance improvements of stool-based screening tests

    2010, Best Practice and Research: Clinical Gastroenterology
    Citation Excerpt :

    The evidence on the effect of vitamin C use on test performance was inconclusive [15]. The use of aspirin or NSAIDs does not seem to increase false-positivity of the Hemoccult II and Hemoccult II SENSA [16,17]. Thus, physicians do not need to advise participants to restrict their diet and/or medication prior to gFOBT, although usually advised otherwise by test manufacturers.

View all citing articles on Scopus

Supported in part by an unrestricted grant from SmithKline Diagnostics; SmithKline Diagnostics supplied materials for fecal occult blood testing.

View full text